Universe Common Stock Shares Outstanding vs Total Current Liabilities Analysis

UPC Stock

USD 0.23 0.01 4.17%

Universe Pharmaceuticals financial indicator trend analysis is much more than just breaking down Universe Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Universe Pharmaceuticals is a good investment. Please check the relationship between Universe Pharmaceuticals Common Stock Shares Outstanding and its Total Current Liabilities accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.

Common Stock Shares Outstanding vs Total Current Liabilities

Common Stock Shares Outstanding vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Universe Pharmaceuticals Common Stock Shares Outstanding account and Total Current Liabilities. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Universe Pharmaceuticals' Common Stock Shares Outstanding and Total Current Liabilities is 0.84. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Universe Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Universe Pharmaceuticals' Common Stock Shares Outstanding and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Universe Pharmaceuticals are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Common Stock Shares Outstanding i.e., Universe Pharmaceuticals' Common Stock Shares Outstanding and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Current Liabilities

Total Current Liabilities is an item on Universe Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Universe Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Universe Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Universe Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.As of September 28, 2024, Tax Provision is expected to decline to about 1.6 M. In addition to that, Selling General Administrative is expected to decline to about 1.8 M

	2021	2022	2023	2024 (projected)
Interest Expense	162.4K	156.8K	180.3K	153.8K
Depreciation And Amortization	533.9K	508.8K	457.9K	413.1K

Interest Expense Depreciation And Amortization

Universe Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Long Term Investments	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		0.85	-0.56	-0.2	0.97	0.97	0.96	-0.34	0.42	0.83	0.88	0.21	0.98	0.93	0.98	0.93	-0.34	-0.65	-0.62	0.68	0.96	-0.2	0.97	-0.4	0.91	0.85
Short Long Term Debt Total	0.85		-0.59	-0.18	0.83	0.89	0.95	-0.44	0.65	0.59	0.88	-0.02	0.9	0.88	0.9	0.68	-0.44	-0.67	-0.6	0.33	0.93	-0.18	0.85	-0.61	0.96	1.0
Other Current Liab	-0.56	-0.59		0.89	-0.73	-0.73	-0.61	0.35	-0.38	-0.8	-0.44	-0.1	-0.62	-0.66	-0.64	-0.64	0.35	0.97	0.97	-0.46	-0.63	0.89	-0.73	0.45	-0.58	-0.59
Total Current Liabilities	-0.2	-0.18	0.89		-0.43	-0.4	-0.24	0.12	-0.12	-0.62	-0.01	-0.07	-0.27	-0.31	-0.29	-0.39	0.12	0.84	0.86	-0.31	-0.28	1.0	-0.42	0.19	-0.21	-0.18
Total Stockholder Equity	0.97	0.83	-0.73	-0.43		0.99	0.95	-0.34	0.42	0.92	0.81	0.21	0.97	0.94	0.98	0.95	-0.34	-0.81	-0.78	0.7	0.96	-0.43	1.0	-0.42	0.89	0.83
Net Tangible Assets	0.97	0.89	-0.73	-0.4	0.99		0.97	-0.33	0.46	0.88	0.85	0.17	0.98	0.94	0.99	0.92	-0.33	-0.8	-0.77	0.65	0.98	-0.4	1.0	-0.43	0.93	0.89
Property Plant And Equipment Net	0.96	0.95	-0.61	-0.24	0.95	0.97		-0.38	0.6	0.75	0.89	0.03	0.99	0.95	0.97	0.84	-0.38	-0.71	-0.65	0.54	1.0	-0.24	0.96	-0.51	0.98	0.95
Current Deferred Revenue	-0.34	-0.44	0.35	0.12	-0.34	-0.33	-0.38		-0.55	-0.28	-0.37	-0.11	-0.36	-0.59	-0.36	-0.33	1.0	0.36	0.36	0.04	-0.36	0.12	-0.35	0.94	-0.38	-0.44
Net Debt	0.42	0.65	-0.38	-0.12	0.42	0.46	0.6	-0.55		0.14	0.4	-0.65	0.55	0.64	0.42	0.22	-0.55	-0.42	-0.35	-0.06	0.59	-0.12	0.44	-0.76	0.65	0.65
Retained Earnings	0.83	0.59	-0.8	-0.62	0.92	0.88	0.75	-0.28	0.14		0.64	0.42	0.81	0.79	0.85	0.94	-0.28	-0.83	-0.84	0.79	0.77	-0.62	0.91	-0.26	0.65	0.59
Accounts Payable	0.88	0.88	-0.44	-0.01	0.81	0.85	0.89	-0.37	0.4	0.64		0.23	0.85	0.81	0.87	0.7	-0.37	-0.47	-0.41	0.62	0.84	-0.01	0.83	-0.4	0.81	0.88
Cash	0.21	-0.02	-0.1	-0.07	0.21	0.17	0.03	-0.11	-0.65	0.42	0.23		0.06	0.08	0.25	0.4	-0.11	-0.1	-0.17	0.34	0.02	-0.07	0.2	0.12	-0.05	-0.02
Non Current Assets Total	0.98	0.9	-0.62	-0.27	0.97	0.98	0.99	-0.36	0.55	0.81	0.85	0.06		0.96	0.98	0.89	-0.36	-0.72	-0.67	0.61	0.99	-0.27	0.98	-0.47	0.95	0.9
Other Assets	0.93	0.88	-0.66	-0.31	0.94	0.94	0.95	-0.59	0.64	0.79	0.81	0.08	0.96		0.94	0.87	-0.59	-0.75	-0.71	0.5	0.95	-0.31	0.94	-0.67	0.92	0.88
Cash And Short Term Investments	0.98	0.9	-0.64	-0.29	0.98	0.99	0.97	-0.36	0.42	0.85	0.87	0.25	0.98	0.94		0.93	-0.36	-0.74	-0.71	0.61	0.97	-0.29	0.98	-0.45	0.94	0.9
Net Receivables	0.93	0.68	-0.64	-0.39	0.95	0.92	0.84	-0.33	0.22	0.94	0.7	0.4	0.89	0.87	0.93		-0.33	-0.73	-0.75	0.7	0.86	-0.39	0.94	-0.34	0.78	0.68
Common Stock Total Equity	-0.34	-0.44	0.35	0.12	-0.34	-0.33	-0.38	1.0	-0.55	-0.28	-0.37	-0.11	-0.36	-0.59	-0.36	-0.33		0.36	0.36	0.04	-0.36	0.12	-0.35	0.94	-0.38	-0.44
Common Stock Shares Outstanding	-0.65	-0.67	0.97	0.84	-0.81	-0.8	-0.71	0.36	-0.42	-0.83	-0.47	-0.1	-0.72	-0.75	-0.74	-0.73	0.36		0.99	-0.41	-0.74	0.84	-0.81	0.49	-0.7	-0.67
Inventory	-0.62	-0.6	0.97	0.86	-0.78	-0.77	-0.65	0.36	-0.35	-0.84	-0.41	-0.17	-0.67	-0.71	-0.71	-0.75	0.36	0.99		-0.42	-0.69	0.86	-0.78	0.47	-0.64	-0.6
Other Current Assets	0.68	0.33	-0.46	-0.31	0.7	0.65	0.54	0.04	-0.06	0.79	0.62	0.34	0.61	0.5	0.61	0.7	0.04	-0.41	-0.42		0.53	-0.31	0.69	0.14	0.37	0.33
Other Stockholder Equity	0.96	0.93	-0.63	-0.28	0.96	0.98	1.0	-0.36	0.59	0.77	0.84	0.02	0.99	0.95	0.97	0.86	-0.36	-0.74	-0.69	0.53		-0.28	0.96	-0.5	0.98	0.93
Total Liab	-0.2	-0.18	0.89	1.0	-0.43	-0.4	-0.24	0.12	-0.12	-0.62	-0.01	-0.07	-0.27	-0.31	-0.29	-0.39	0.12	0.84	0.86	-0.31	-0.28		-0.42	0.19	-0.21	-0.18
Net Invested Capital	0.97	0.85	-0.73	-0.42	1.0	1.0	0.96	-0.35	0.44	0.91	0.83	0.2	0.98	0.94	0.98	0.94	-0.35	-0.81	-0.78	0.69	0.96	-0.42		-0.43	0.9	0.85
Long Term Investments	-0.4	-0.61	0.45	0.19	-0.42	-0.43	-0.51	0.94	-0.76	-0.26	-0.4	0.12	-0.47	-0.67	-0.45	-0.34	0.94	0.49	0.47	0.14	-0.5	0.19	-0.43		-0.57	-0.61
Property Plant And Equipment Gross	0.91	0.96	-0.58	-0.21	0.89	0.93	0.98	-0.38	0.65	0.65	0.81	-0.05	0.95	0.92	0.94	0.78	-0.38	-0.7	-0.64	0.37	0.98	-0.21	0.9	-0.57		0.96
Short Long Term Debt	0.85	1.0	-0.59	-0.18	0.83	0.89	0.95	-0.44	0.65	0.59	0.88	-0.02	0.9	0.88	0.9	0.68	-0.44	-0.67	-0.6	0.33	0.93	-0.18	0.85	-0.61	0.96

Click cells to compare fundamentals

Universe Pharmaceuticals Account Relationship Matchups

Universe Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	28.8M	70.1M	59.5M	53.3M	61.3M	47.2M
Short Long Term Debt Total	2.6M	4.3M	3.9M	5.5M	6.3M	3.9M
Other Current Liab	2.7M	1.6M	6.1M	3.7M	3.3M	3.6M
Total Current Liabilities	8.0M	11.2M	13.1M	13.8M	15.8M	12.8M
Total Stockholder Equity	20.8M	58.9M	46.4M	39.5M	45.5M	34.4M
Net Tangible Assets	12.2M	20.6M	58.8M	46.3M	53.2M	32.4M
Property Plant And Equipment Net	4.4M	15.4M	13.6M	15.0M	17.2M	10.6M
Net Debt	(7.4M)	(3.7M)	(1.8M)	197.2K	226.8K	238.1K
Retained Earnings	13.7M	25.1M	16.3M	10.2M	11.7M	13.6M
Accounts Payable	2.7M	5.3M	3.1M	4.6M	5.3M	3.8M
Cash	10.1M	8.1M	5.7M	5.3M	6.1M	7.1M
Non Current Assets Total	5.5M	19.7M	18.0M	16.5M	18.9M	13.1M
Other Assets	168.1K	186.5K	14.1M	12.9M	14.9M	15.6M
Cash And Short Term Investments	10.1M	21.8M	18.9M	18.5M	21.3M	14.4M
Net Receivables	10.9M	15.8M	15.2M	10.7M	12.3M	12.2M
Liabilities And Stockholders Equity	28.8M	70.1M	59.5M	53.3M	61.3M	47.2M
Inventory	1.9M	2.5M	2.2M	3.3M	3.0M	2.8M
Other Current Assets	443.7K	10.4M	1.7M	626.2K	720.2K	684.2K
Total Liab	8.0M	11.2M	13.1M	13.8M	15.8M	12.8M
Net Invested Capital	23.4M	63.3M	50.4M	45.0M	51.8M	38.4M
Long Term Investments	735K	744.9K	702.9K	685.3K	616.8K	572.9K
Property Plant And Equipment Gross	4.4M	15.4M	19.3M	21.0M	24.2M	12.8M
Short Long Term Debt	2.6M	4.3M	3.9M	5.5M	6.3M	3.9M
Total Current Assets	23.3M	50.5M	41.5M	36.8M	42.3M	34.1M
Accumulated Other Comprehensive Income	3.3M	4.5M	772.8K	26.3K	23.6K	22.5K
Net Working Capital	15.3M	39.3M	28.4M	23.1M	26.5M	21.3M
Short Term Debt	2.6M	4.3M	3.9M	5.5M	6.3M	3.9M
Intangible Assets	174.8K	178.5K	157.5K	148.6K	133.7K	135.3K
Property Plant Equipment	4.6M	4.4M	4.7M	4.3M	3.8M	3.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

S	SentinelOne
MSFT	Microsoft
MSFT	Microsoft

Additional Information and Resources on Investing in Universe Stock

When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:

How To Invest In Universe

Details

Is Universe Stock a good investment?

Details

What is Universe Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.82)

Earnings Share

(5.09)

Revenue Per Share

7.351

Quarterly Revenue Growth

(0.30)

Return On Assets

(0.06)

The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Universe Common Stock Shares Outstanding vs Total Current Liabilities Analysis

Common Stock Shares Outstanding vs Total Current Liabilities

Common Stock Shares Outstanding vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Total Current Liabilities

Universe Pharmaceuticals fundamental ratios Correlations

Universe Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Universe Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Information and Resources on Investing in Universe Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Long Term Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Net Tangible Assets
Other Stockholder Equity	+ 1.0	Property Plant And Equipment Net
Common Stock Total Equity	+ 1.0	Current Deferred Revenue

Inventory	- 0.84	Retained Earnings
Common Stock Shares Outstanding	- 0.83	Retained Earnings
Net Invested Capital	- 0.81	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.81	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.8	Net Tangible Assets
Retained Earnings	- 0.8	Other Current Liab